Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents

Circulation Journal

Volumn 75, Issue 5, 2011, Pages 1098-1106

  Dohi, Tomotaka ^a   Miyauchi, Katsumi ^a   Iesaki, Takafumi ^a   Tsuruta, Ryo ^a   Tsuboi, Shuta ^a   Ogita, Manabu ^a   Kubota, Naozumi ^a   Kasai, Takatoshi ^a   Yokoyama, Takayuki ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Endothelial dysfunction; Inflammation; Sirolimus eluting stent; Thiazolidinedione

Indexed keywords

ACETYLSALICYLIC ACID; BRADYKININ; CANDESARTAN; CLOPIDOGREL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPARIN; PIOGLITAZONE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY WEIGHT; CELL ADHESION; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; CORONARY STENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART MUSCLE RELAXATION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SWINE; SYSTOLIC BLOOD PRESSURE; VASCULITIS; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CORONARY VESSELS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; INFLAMMATION; PROTECTIVE AGENTS; SIROLIMUS; SUS SCROFA; TETRAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 79955679491     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0917     Document Type: Article

References (45)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
3. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
4. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, et al. Drug-eluting stent thrombosis: Results from apooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-959.
5. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis:Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441.
6. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J AmColl Cardiol 2004; 44: 1373-1385.
7. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
8. Katoh H, Shite J, Shinke T, Matsumoto D, Tanino Y, Ogasawara D, et al. Delayed neointimalization on sirolimus-eluting stents: 6-month and 12-month follow up by optical coherence tomography. Circ J 2009; 73: 1033-1037.
9. Li J, Jabara R, Pendyala L, Otsuka Y, Shinke T, Hou D, et al. Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv 2008; 1: 279-285.
10. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129.
11. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: Evidence for device-specific responses. Circ Cardiovasc Interv 2008; 1: 193-200.
12. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
13. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208-1212.
14. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905-910.
15. Hornig B, Kohler C, Schlink D, Tatge H, Drexler H. AT1-receptor antagonism improves endothelial function in coronary artery diseaseby a bradykinin/B2-receptor-dependent mechanism. Hypertension 2003; 41: 1092-1095.
16. Preumont N, Unger P, Goldman S, Berkenboom G. Effect of longterm angiotensin II type I receptor antagonism on peripheral and coronary vasomotion. Cardiovasc Drugs Ther 2004; 18: 197-202.
17. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
18. Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 2009; 73: 214-220.
19. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferatoractivated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178.
20. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 2008; 197: 612-619.
21. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
22. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996; 16: 1312-1318.
23. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis 2004; 174: 253-259.
24. Otsuka A, Azuma K, Iesaki T, Sato F, Hirose T, Shimizu T, et al. Temporary hyperglycaemia provokes monocyte adhesion to endothelialcells in rat thoracic aorta. Diabetologia 2005; 48: 2667-2674.
25. Iesaki T, Gupte SA, Kaminski PM, Wolin MS. Inhibition of guanylate cyclase stimulation by NO and bovine arterial relaxation to peroxynitrite and H2O2. Am J Physiol 1999; 277: H978-H985.
26. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smoothmuscle cells. Circ Res 1995; 76: 412-417.
27. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J ClinInvest 1996; 98: 2277-2283.
28. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet- derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
29. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP. Comparative study of cyclosporine and tacrolimus vs newerimmunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002; 21: 990-998.
30. Brott BC, Anayiotos AS, Chapman GD, Anderson PG, Hillegass WB. Severe, diffuse coronary artery spasm after drug-eluting stent placement. J Invasive Cardiol 2006; 18: 584-592.
31. Akishita M, Nagai K, Xi H, Yu W, Sudoh N, Watanabe T, et al. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 2005; 45: 1188-1193.
32. Jabs A, Gobel S, Wenzel P, Kleschyov AL, Hortmann M, Oelze M, et al. Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase- dependent superoxide production and decreased vascular nitric oxide formation. J Am Coll Cardiol 2008; 51: 2130-2138.
33. Flesch M, Hoper A, Dell'Italia L, Evans K, Bond R, Peshock R, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003; 108: 598-604.
34. Krasinski K, Spyridopoulos I, Kearney M, Losordo DW. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation 2001; 104: 1754-1756.
35. Blum A, Miller H. Role of cytokines in heart failure. Am Heart J 1998; 135: 181-186.
36. Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR. Differential effects of at1 receptor and ca2+ channel blockade on atherosclerosis,inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 2007; 195: 39-47.
37. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-57.
38. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, et al. Peroxisome proliferator-activated receptor gamma activators down regulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000; 102: 1834-1839.
39. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-726.
40. Nomura H, Yamawaki H, Mukohda M, Okada M, Hara Y. Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel. J Pharmacol Sci 2008; 108: 258-265.
41. Imanishi T, Kobayashi K, Kuki S, Takahashi C, Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 2006; 189: 288-296.
42. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301.
43. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: Insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978-1985.
44. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11: 21-30.
45. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, et al. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptorgamma in vascular smooth muscle cells. Endocrinology 2001; 142: 3125-3134.